Skip to content

Virtual Reality-Enabled Treatment of Nightmares

P. Mcnamara, Ken Moore, Y. Papelis, S. Diallo, W. Wildman

Dreaming September 1, 2018 DOI: 10.1037/drm0000088 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pilot trial Randomized Placebo-controlled Double-blind Pilot study Peer reviewed
Sample size 19
Population Community volunteers averaging 49 years of age with varying levels of nightmare distress
Intervention Virtual reality-based imagery rehearsal and rescripting treatment (ReScript)
Duration 4-week trial with 2 sessions per week
Topics Dreaming
Key findings ReScript was associated with significant reductions from baseline to trial end in anxiety, nightmare distress, and nightmare effects (all effect sizes 0.63 or above), plus a small significant reduction in nightmare frequency and no reported significant side or adverse effects. The authors conclude ReScript may be a safe and effective short-term therapy for nightmare distress but should next be tested in a randomized, double-blind, placebo-controlled trial.

Abstract

We pilot tested the efficacy of a virtual reality-based imagery rehearsal and rescripting treatment (ReScript) for nightmares. Nineteen community volunteers (Mage = 49 years) who varied in terms of their nightmare distress levels participated in a 4-week-long trial of ReScript therapy. Participants used VR manual controls in an Oculus headset to manipulate 3 scary or threatening images per session with 2 sessions per week. The object was to manipulate these images into less scary or threatening images so as to gain cognitive control over intrusive imagery and to lessen overall anxiety or nightmare distress or nightmare daytime effects. Images were taken from the International Affective Picture System database and varied along 3 affective dimensions (valence, arousal, and dominance) important for nightmare imagery. Results demonstrated a significant reduction (from baseline to trial end) in anxiety levels, nightmare distress, and nightmare effects (all effect sizes .63 or above), as well as a significant decrease in anxiety words and a significant increase in cognitive process words in rescripted narratives. Nightmare frequency was also significantly reduced though effect size was small. No significant side or adverse effects were reported by participants during the 4-week trial. Indeed, Depersonalization and Posttraumatic Stress Disorder Symptom Checklist scores significantly declined and mood function tests improved over the 4-week trial. We conclude that ReScript may be a safe and effective short-term therapy for nightmare distress but should next be tested with a randomized, double-blind, placebo-controlled trial.

Comparable studies

Other non-randomized and open-label trials on dreaming, most cited first.

Study Year Design Participants
A combined group treatment for nightmares and insomnia in combat veterans: A pilot study Combat veterans with PTSD 2009 Open clinical trial n = 10
Cognitions in Sleep: Lucid Dreaming as an Intervention for Nightmares in Patients With Posttraumatic Stress Disorder. Patients suffering from posttraumatic stress disorder (PTSD) 2020 Pre-post intervention study
Managing Insomnia Using Lucid Dreaming Training: A Pilot Study. Adults with Insomnia Disorder 2021 Open-label trial n = 48
Dream content and political ideology. U.S. adults who identified as members of the political right or political left (28 per... 2002 Pilot study n = 56
Imagery rehearsal therapy for the treatment of nightmares in individuals with borderline personality disorder – A pilot study Individuals with borderline personality disorder 2024 Between-subjects design, pilot study n = 44

Citations in the library

Explore topics